Skip to content
Screener

Celldex Therapeutics CLDX EPS (Diluted)

EPS (Diluted) at other companies

Eli Lilly logo
Eli LillyLLY
$7.94+26.2%
Pfizer logo
PfizerPFE
-$0.04-108%
Rogers Corporation logo
Rogers CorporationROG
$0.76+119%
Amgen logo
AmgenAMGN
$4.37+64.9%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$12.23-4.5%
Incyte logo
IncyteINCY
$2.81+37.7%

Other financials

Income statement

See full
Revenue$22.0K-97.0%
Operating income-$80.6M-26.3%
Net income-$73.5M-29.9%

Balance sheet

See full
Cash & equivalents$47.5M+106%
Total debt$4.9M+61.8%
Total equity$714.6M+9.0%
Total assets$782.3M+13.0%

Cash flow

See full
Operating cash flow-$57.4M-30.5%
CapEx$3.2M+337%
Free cash flow-$60.6M-35.4%

Valuation

See full
Market cap$3.26B+129%
Enterprise value$3.22B+129%
P/S20,646.4×+20,401×

Profitability

See full
Operating margin-206,220.3%-210,440pp
Net margin-190,220.9%-193,797pp
FCF margin-153,231%-156,630pp

Returns & leverage

See full
Return on equity-43.9%+70.0pp
Debt / equity0×0.0×
Current ratio11.8×-7.8×

Where this comes from

Reported directly by Celldex Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.

The source filing: Celldex Therapeutics’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 4:06 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001104659-26-091984
Line itemThree Months Ended / June 30, 2026Three Months Ended / June 30, 2025Six Months Ended / June 30, 2026Six Months Ended / June 30, 2025
Operating loss(80,623)(63,857)(165,058)(126,597)
Investment and other income, net7,1207,25712,87016,201
Net loss$(73,503)$(56,600)$(152,188)$(110,396)
Basic and diluted net loss per common share$(0.94)$(0.85)$(2.11)$(1.66)
Shares used in calculating basic and diluted net loss per share77,84066,39272,23466,388
Comprehensive loss:
Net loss$(73,503)$(56,600)$(152,188)$(110,396)
Other comprehensive (loss) income:

Item 1. Unaudited Financial Statements

FAQ

What is Celldex Therapeutics's EPS (diluted)?
Celldex Therapeutics (CLDX) reported EPS (diluted) of -$0.94 in Q2 2026.
How has Celldex Therapeutics's EPS (diluted) changed year-over-year?
Celldex Therapeutics's EPS (diluted) decreased by 10.6% year-over-year, from -$0.85 to -$0.94.
What is the long-term trend for Celldex Therapeutics's EPS (diluted)?
Over 4 years (2021 to 2025), Celldex Therapeutics's EPS (diluted) has grown at a 24.2% compound annual growth rate (CAGR), from -$1.64 to -$3.90.
What does EPS (diluted) mean?
Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.

Ask your AI about Celldex Therapeutics's eps (diluted).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude